Holen Sie sich die Stockscreener-App
13.99
2.34%
0.32
Handel nachbörslich:
13.99
Schlusskurs vom Vortag:
$13.67
Offen:
$13.59
24-Stunden-Volumen:
169.31K
Relative Volume:
0.53
Marktkapitalisierung:
$184.00M
Einnahmen:
$1.93M
Nettoeinkommen (Verlust:
$-7.96M
KGV:
-0.00396
EPS:
-3530.8178
Netto-Cashflow:
$-36.78M
1W Leistung:
+3.78%
1M Leistung:
+31.30%
6M Leistung:
+160.04%
1J Leistung:
+50.59%
1-Tages-Spanne:
$13.37
$14.23
1-Wochen-Bereich:
$13.20
$15.99
52-Wochen-Spanne:
$3.39
$16.00
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Firmenname
Avalo Therapeutics Inc
Sektor
Branche
Telefon
410-522-8707
Adresse
1500 LIBERTY RIDGE DRIVE, WAYNE
Vergleichen Sie AVTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
13.99 | 243.33M | 1.93M | -7.96M | -36.78M | -3,530.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Bestätigt | H.C. Wainwright | Buy |
| 2025-09-05 | Eingeleitet | TD Cowen | Buy |
| 2025-08-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-03-25 | Eingeleitet | Jefferies | Buy |
| 2025-03-25 | Eingeleitet | Stifel | Buy |
| 2025-02-28 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-21 | Eingeleitet | Wedbush | Outperform |
| 2024-12-19 | Eingeleitet | BTIG Research | Buy |
| 2024-10-24 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-04-16 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-09-24 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Avalo Therapeutics Inc Aktie (AVTX) Neueste Nachrichten
Will Avalo Therapeutics Inc. stock keep outperforming rivalsJuly 2025 Analyst Calls & Community Verified Swing Trade Signals - newser.com
Technical analysis overview for Avalo Therapeutics Inc. stockWeekly Stock Analysis & Free Safe Capital Growth Stock Tips - newser.com
Is this a good reentry point in Avalo Therapeutics Inc.Quarterly Portfolio Review & Technical Analysis for Trade Confirmation - newser.com
Avalo Therapeutics Inc. stock trend forecast2025 Valuation Update & Community Supported Trade Ideas - newser.com
Market reaction to Avalo Therapeutics Inc.’s recent newsBear Alert & Fast Gain Swing Alerts - newser.com
How Avalo Therapeutics Inc. (C6K0) stock responds to job market shiftsJuly 2025 Intraday Action & Daily Oversold Bounce Ideas - newser.com
Brokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) PT at $31.67 - Defense World
Real time social sentiment graph for Avalo Therapeutics Inc.Weekly Market Report & Weekly Top Gainers Alerts - newser.com
Will Avalo Therapeutics Inc. stock deliver long term returnsJuly 2025 News Drivers & Intraday High Probability Setup Alerts - newser.com
Why Avalo Therapeutics Inc. stock remains on watchlists2025 Momentum Check & Daily Stock Momentum Reports - newser.com
Multi factor analysis applied to Avalo Therapeutics Inc.Weekly Trade Analysis & Risk Controlled Daily Trade Plans - newser.com
Is it time to cut losses on Avalo Therapeutics Inc.July 2025 Snapshot & Capital Efficient Trading Techniques - newser.com
Will Avalo Therapeutics Inc. stock benefit from upcoming earnings reportsEarnings Performance Report & Daily Oversold Stock Bounce Ideas - newser.com
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
How high can Avalo Therapeutics Inc. stock goJuly 2025 Macro Moves & Entry and Exit Point Strategies - newser.com
Avalo Therapeutics, Inc. Updates Investor Presentation - TradingView
Should I buy Avalo Therapeutics Inc. (C6K0) stock before earnings season2025 Year in Review & Fast Entry and Exit Trade Plans - newser.com
How Avalo Therapeutics Inc. stock performs in weak economyRecession Risk & Smart Swing Trading Techniques - newser.com
Can Avalo Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 Analyst Calls & High Accuracy Swing Entry Alerts - newser.com
Will Avalo Therapeutics Inc. see short term momentumWall Street Watch & Low Risk Growth Stock Ideas - newser.com
Is Avalo Therapeutics Inc. (C6K0) stock positioned for secular growthRate Hike & Breakout Confirmation Alerts - newser.com
How moving averages guide Avalo Therapeutics Inc. trading2025 Biggest Moves & AI Driven Stock Reports - newser.com
Can Avalo Therapeutics Inc. (C6K0) stock sustain revenue momentum2025 Technical Patterns & Reliable Price Action Trade Plans - newser.com
Is Avalo Therapeutics Inc a good long term investmentRisk Mitigation Techniques & Free Superior Profit Margins - earlytimes.in
Why Avalo Therapeutics Inc. (C6K0) stock remains top rated2025 Market Outlook & AI Forecasted Entry/Exit Points - newser.com
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Sees Significant Increase in Short Interest - Defense World
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update - MarketBeat
Avalo Therapeutics Strengthens Leadership with Key Appointments - The Globe and Mail
Avalo Therapeutics Expands Leadership Team with Key - GlobeNewswire
Avalo Therapeutics, Inc. Announces Board Appointments, Effective October 1, 2025 - MarketScreener
Avalo Therapeutics expands leadership with two senior appointments By Investing.com - Investing.com Canada
Avalo Therapeutics expands leadership with two senior appointments - Investing.com India
Former Longboard $2.6B Deal Architect Joins Avalo Therapeutics as CBO Ahead of Key Trial Results - Stock Titan
BTIG Research Reiterates “Buy” Rating for Avalo Therapeutics (NASDAQ:AVTX) - Defense World
Avalo Therapeutics' (AVTX) Buy Rating Reiterated at BTIG Research - MarketBeat
Finanzdaten der Avalo Therapeutics Inc-Aktie (AVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):